SU‐E‐T‐713: Radiobiological Evaluation of the Inter‐Fractional Variations in Cervical Cancer Treatments with HDR Brachytherapy

B. Tuazon, C. Esquivel, T. Biggers, P. Mavroidis, Sotirios Stathakis, T. Eng, Nikos Papanikolaou

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to evaluate the treatment of cervical cancer using high dose rate iridium‐192 tandem and ovoids using a deformable registration software and employing dosimetric and radiobiological measures. 'Methods: High‐dose‐rate tandem and ovoid treatments using an iridium‐192 source were planned in the Oncentra treatment planning system. Each of the 17 patients was given six fractions with total dose of about 35 Gy to point A. Using the VelocityAI software, the image sets from all the HDR procedures were registered to the first fraction CT image set using either rigid or deformable registration. The dose files were added together using the registration image sets. The contours of the organs at risk created in Oncentra were imported into the VelocityAI for the calculation of the DVHs. The biological effective doses (BED), biologically effective uniform doses (BEUD) and generalized equivalent uniform doses (gEUD) were additionally obtained. Results: In one patient, the physical mean, BED, gEUD and BEUD doses to the target, rectum and bladder by the extrapolated first fraction of the HDR brachytherapy were 56.1, 189.3, 9.1 and 49.1 Gy for the target; 7.5, 7.4, 16.9 and 43.3 Gy for the rectum, 9.7, 9.7, 14.7 and 34.3 Gy for the bladder, respectively. For the combined deformed dose distribution, the average physical, BED, gEUD and BEUD doses were 42.9, 76.7, 4.1 and 65.3 Gy for the target, 4.2, 2.5, 5.9 and 26.3 Gy for the rectum and 4.6, 1.8, 5.3 and 0.0 Gy for the bladder, respectively. Conclusion: It appears that the dose distributions in the organs between different HDR brachytherapy fractions can vary considerably. The individual fractional dose distributions tend to overestimate the doses that are received by the different organs.

Original languageEnglish (US)
Pages (from-to)370
Number of pages1
JournalMedical Physics
Volume40
Issue number6
DOIs
StatePublished - 2013

Fingerprint

Brachytherapy
Rectum
Uterine Cervical Neoplasms
Urinary Bladder
Software
Organs at Risk
Therapeutics

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

SU‐E‐T‐713 : Radiobiological Evaluation of the Inter‐Fractional Variations in Cervical Cancer Treatments with HDR Brachytherapy. / Tuazon, B.; Esquivel, C.; Biggers, T.; Mavroidis, P.; Stathakis, Sotirios; Eng, T.; Papanikolaou, Nikos.

In: Medical Physics, Vol. 40, No. 6, 2013, p. 370.

Research output: Contribution to journalArticle

Tuazon, B. ; Esquivel, C. ; Biggers, T. ; Mavroidis, P. ; Stathakis, Sotirios ; Eng, T. ; Papanikolaou, Nikos. / SU‐E‐T‐713 : Radiobiological Evaluation of the Inter‐Fractional Variations in Cervical Cancer Treatments with HDR Brachytherapy. In: Medical Physics. 2013 ; Vol. 40, No. 6. pp. 370.
@article{027bae478d3c430b8ae21a7943c2a31b,
title = "SU‐E‐T‐713: Radiobiological Evaluation of the Inter‐Fractional Variations in Cervical Cancer Treatments with HDR Brachytherapy",
abstract = "Purpose: The purpose of this study was to evaluate the treatment of cervical cancer using high dose rate iridium‐192 tandem and ovoids using a deformable registration software and employing dosimetric and radiobiological measures. 'Methods: High‐dose‐rate tandem and ovoid treatments using an iridium‐192 source were planned in the Oncentra treatment planning system. Each of the 17 patients was given six fractions with total dose of about 35 Gy to point A. Using the VelocityAI software, the image sets from all the HDR procedures were registered to the first fraction CT image set using either rigid or deformable registration. The dose files were added together using the registration image sets. The contours of the organs at risk created in Oncentra were imported into the VelocityAI for the calculation of the DVHs. The biological effective doses (BED), biologically effective uniform doses (BEUD) and generalized equivalent uniform doses (gEUD) were additionally obtained. Results: In one patient, the physical mean, BED, gEUD and BEUD doses to the target, rectum and bladder by the extrapolated first fraction of the HDR brachytherapy were 56.1, 189.3, 9.1 and 49.1 Gy for the target; 7.5, 7.4, 16.9 and 43.3 Gy for the rectum, 9.7, 9.7, 14.7 and 34.3 Gy for the bladder, respectively. For the combined deformed dose distribution, the average physical, BED, gEUD and BEUD doses were 42.9, 76.7, 4.1 and 65.3 Gy for the target, 4.2, 2.5, 5.9 and 26.3 Gy for the rectum and 4.6, 1.8, 5.3 and 0.0 Gy for the bladder, respectively. Conclusion: It appears that the dose distributions in the organs between different HDR brachytherapy fractions can vary considerably. The individual fractional dose distributions tend to overestimate the doses that are received by the different organs.",
author = "B. Tuazon and C. Esquivel and T. Biggers and P. Mavroidis and Sotirios Stathakis and T. Eng and Nikos Papanikolaou",
year = "2013",
doi = "10.1118/1.4815140",
language = "English (US)",
volume = "40",
pages = "370",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - SU‐E‐T‐713

T2 - Radiobiological Evaluation of the Inter‐Fractional Variations in Cervical Cancer Treatments with HDR Brachytherapy

AU - Tuazon, B.

AU - Esquivel, C.

AU - Biggers, T.

AU - Mavroidis, P.

AU - Stathakis, Sotirios

AU - Eng, T.

AU - Papanikolaou, Nikos

PY - 2013

Y1 - 2013

N2 - Purpose: The purpose of this study was to evaluate the treatment of cervical cancer using high dose rate iridium‐192 tandem and ovoids using a deformable registration software and employing dosimetric and radiobiological measures. 'Methods: High‐dose‐rate tandem and ovoid treatments using an iridium‐192 source were planned in the Oncentra treatment planning system. Each of the 17 patients was given six fractions with total dose of about 35 Gy to point A. Using the VelocityAI software, the image sets from all the HDR procedures were registered to the first fraction CT image set using either rigid or deformable registration. The dose files were added together using the registration image sets. The contours of the organs at risk created in Oncentra were imported into the VelocityAI for the calculation of the DVHs. The biological effective doses (BED), biologically effective uniform doses (BEUD) and generalized equivalent uniform doses (gEUD) were additionally obtained. Results: In one patient, the physical mean, BED, gEUD and BEUD doses to the target, rectum and bladder by the extrapolated first fraction of the HDR brachytherapy were 56.1, 189.3, 9.1 and 49.1 Gy for the target; 7.5, 7.4, 16.9 and 43.3 Gy for the rectum, 9.7, 9.7, 14.7 and 34.3 Gy for the bladder, respectively. For the combined deformed dose distribution, the average physical, BED, gEUD and BEUD doses were 42.9, 76.7, 4.1 and 65.3 Gy for the target, 4.2, 2.5, 5.9 and 26.3 Gy for the rectum and 4.6, 1.8, 5.3 and 0.0 Gy for the bladder, respectively. Conclusion: It appears that the dose distributions in the organs between different HDR brachytherapy fractions can vary considerably. The individual fractional dose distributions tend to overestimate the doses that are received by the different organs.

AB - Purpose: The purpose of this study was to evaluate the treatment of cervical cancer using high dose rate iridium‐192 tandem and ovoids using a deformable registration software and employing dosimetric and radiobiological measures. 'Methods: High‐dose‐rate tandem and ovoid treatments using an iridium‐192 source were planned in the Oncentra treatment planning system. Each of the 17 patients was given six fractions with total dose of about 35 Gy to point A. Using the VelocityAI software, the image sets from all the HDR procedures were registered to the first fraction CT image set using either rigid or deformable registration. The dose files were added together using the registration image sets. The contours of the organs at risk created in Oncentra were imported into the VelocityAI for the calculation of the DVHs. The biological effective doses (BED), biologically effective uniform doses (BEUD) and generalized equivalent uniform doses (gEUD) were additionally obtained. Results: In one patient, the physical mean, BED, gEUD and BEUD doses to the target, rectum and bladder by the extrapolated first fraction of the HDR brachytherapy were 56.1, 189.3, 9.1 and 49.1 Gy for the target; 7.5, 7.4, 16.9 and 43.3 Gy for the rectum, 9.7, 9.7, 14.7 and 34.3 Gy for the bladder, respectively. For the combined deformed dose distribution, the average physical, BED, gEUD and BEUD doses were 42.9, 76.7, 4.1 and 65.3 Gy for the target, 4.2, 2.5, 5.9 and 26.3 Gy for the rectum and 4.6, 1.8, 5.3 and 0.0 Gy for the bladder, respectively. Conclusion: It appears that the dose distributions in the organs between different HDR brachytherapy fractions can vary considerably. The individual fractional dose distributions tend to overestimate the doses that are received by the different organs.

UR - http://www.scopus.com/inward/record.url?scp=85024780939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024780939&partnerID=8YFLogxK

U2 - 10.1118/1.4815140

DO - 10.1118/1.4815140

M3 - Article

AN - SCOPUS:85024780939

VL - 40

SP - 370

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -